Combining Quinupristin/Dalfopristin with Other Agents for Resistant Infections

Annals of Pharmacotherapy

Volumn 38, Issue 4, 2004, Pages 677-685

  Brown, Jack ^a   Freeman III, Burgess B ^b,c  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Dalfopristin; Methicillin resistant Staphylococcus aureus; Quinupristin; Synergy; Vancomycin resistant Enterococcus faecium

Indexed keywords

AMPICILLIN; CHLORAMPHENICOL; DALFOPRISTIN PLUS QUINUPRISTIN; DOXYCYCLINE; LINCOSAMIDE; MACROLIDE; MINOCYCLINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOGRAMIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; DOSE RESPONSE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENTIATION; ENTEROCOCCUS; ENTEROCOCCUS FAECIUM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS;

ANTI-BACTERIAL AGENTS; CELL WALL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; ENTEROCOCCUS FAECIUM; HUMANS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; PROTEIN SYNTHESIS INHIBITORS; STAPHYLOCOCCUS AUREUS; VIRGINIAMYCIN;

EID: 1542744059     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D323     Document Type: Review

References (65)

1. National Nosocomial Infections Surveillance (NNIS) System. NNIS system report, data summary from January 1990-May 1999, issued June 1999. Am J Infect Control 1999;27:520-32.
2. Jones RN. Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY antimicrobial surveillance program (1997-2001). Semin Respir Crit Care Med 2003;24:121-33.
3. Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, Enterococcus, gram negative bacilli, Clostridium difficile and Candida. Ann Intern Med 2002;136:834-44.
4. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial testing. 12th ed. 2002;22:96-100.
5. Rybak MJ. Therapeutic options for gram-positive infections. J Hosp Infect 2001;49(suppl A):S25-32.
6. Rybak MJ, Cappelletty DM, Moldovan T, Aeschlimann JR, Kaatz GN. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis and Enterococcus faecium. Antimicrob Agents Chemother 1998;42:721-4.
7. Brumfitt W, Hamilton-Miller JMT, Shah S. In-vitro activity of RP59500, a new semisynthetic streptogramin antibiotic, against gram positive bacteria. J Antimicrob Chemother 1992;30(suppl A):29-37.
8. Hershberger E, Aeschlimann JR, Moldovan T, Rybak MJ. Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovofloxcin and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by time-kill curve methods. Antimicrob Agents Chemother 1999;43:717-21.
9. Inoue M, Okamoto R, Okubo T, Inoue K, Mitsuhashi S. Comparative invitro activity of RP 59500 against clinical bacterial isolates. J Antimicrob Chemother 1992;30(suppl A):45-51.
10. Pugh MD, ed. Stedmans medical dictionary. 27th ed. Philadelphia: Lippincott Williams & Wilkins, 2000:1772.
11. Krogstad DJ, Moellering RC. Antimicrobial combinations. In: Lorian V, ed. Antibiotics in laboratory medicine. Baltimore: Williams & Wilkins, 1986:537-95.
12. Package insert. Synercid (quinupristin-dalfopristin). Bristol, TN: Monarch Pharmaceuticals, June 2002.
13. Bush LM, Calmon J, Cherney CL, Wendeler M, Pitsakis P, Poupard J, et al. High-level penicillin resistance among isolates of enterococci. Implications for treatment of enterococcal infections. Ann Intern Med 1989;110:515-20.
14. Moellering RC. The enterococcus: a classic example of the impact of antimicrobial resistance on therapeutic options. J Antimicrob Chemother 1991;28:1-12.
15. Nachamkin I, Axelrod P, Talbot GH, Fischer SH, Wennersten CB, Moellering RC, et al. Multiply high-level-aminoglycoside-resistant enterococci isolated from patients in a university hospital. J Clin Microbiol 1988;26:1287-91.
16. Williamson R, le Bouguenec C, Gutmann L, Horaud T. One or two low affinity penicillin-binding proteins may be responsible for the range of susceptibility of Enterococcusfaecium to benzylpenicillin. J Gen Microbiol 1985;131:1933-40.
17. Chow JW. Aminoglycoside resistance in enterococci. Clin Infect Dis 2000;31:586-9.
18. Rice EW, Messer JW, Johnson CH, Reasoner DJ. Occurrence of high-level aminoglycoside resistance in environmental isolates of enterococci. Appl Environ Microbiol 1995;61:374-6.
19. Arthur M, Quintiliani R Jr. Regulation of VanA- and VanB-type glycopeptide resistance in enterococci. Antimicrob Agents Chemother 2001;45:375-81.
20. Linden PK, Pasculle AW, Mañez R. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis 1996;22:663-70.
21. Vouillamoz J, Entenza JM, Giddey M, Glauser MP, Moreillon P. In vitro activity of Synercid (quinupristin/dalfopristin) (SYN) combined with other classes of antibiotics against vancomycin-susceptible (VS) E. faecalis and vancomycin-susceptible or resistant (VR) E. faecium (VSEF and VREF) (abstract E8). Presented at: 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 15-18, 1996.
22. Iannini PB, Ehret J, Eickhoff TC. Effects of ampicillin-amikacin and ampicillin-rifampin on enterococci. Antimicrob Agents Chemother 1976;9:448-51.
23. Bozigar PS, Donabedian SM, Zervos MJ, Hershberger E. Activity of quinupristin/dalfopristin compared to linezolid in the treatment of vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in the experimental model of endocarditis in rabbits (abstract 1005). Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, December 16-19, 2001.
24. Eliopoulos GM, Wennersten CB. Antimicrobial activity of quinupristin-dalfopristin combined with other antibiotics against vancomycin-resistant enterococci. Antimicrob Agents Chemother 2002;46:1319-24.
25. Allen GP, Cha R, Rybak MJ. In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2002;46:2606-12.
26. Messick CR, Rodvold KA, Pendland SL. Modified time-kill assay against multidrug-resistant Enterococcus faecium with novel antimicrobial combinations. J Antimicrob Chemother 1999;44:831-4.
27. Thompson RL, Lavin B, Talbot GH. Cure of vancomycin-resistant Enterococcus faecium (VREF) endocarditis with quinupristin/dalfopristin (Q/D) and high-dose ampicillin (AMP) (abstract 538). Presented at: 39th Annual Meeting of the Infectious Disease Society of America, San Francisco, October 25-28, 2001.
28. Matsumura SO, Louie L, Louie M, Simor AE. Synergy testing of vancomycin-resistant Enterococcus faecium and quinupristin-dalfopristin in combination with other antimicrobial agents. Antimicrob Agents Chemother 1999;43:2776-9.
29. Kang SL, Rybak ML. In vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus. J Antimicrob Chemother 1997;39: (suppl A):33-9.
30. Lorian V, Fernandes F. Synergistic activity of vancomycin-quinupristin/dalfopristin combination against Enterococcusfaecium. J Antimicrob Chemother 1997;39(suppl A):63-6.
31. Mercer RC, Penzak SR, Rybak MJ. In vitro activities of an investigational quinolone, glycylcycline, glycopeptide, streptogramin and oxazolidinone tested alone and in combinations against vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 1997;41:2573-5.
32. Baltch AL, Smith RP, Ritz WJ, Bopp LH. Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin resistant Enterococcus faecium. Antimicrob Agents Chemother 1998;42:2564-8.
33. Vasquez D. Binding of chloramphenicol to ribosomes: the effect of a number of antibiotics. Biochem Biophys Acta 1965;114:277-88.
34. Aeschilman JR, Zervos MJ, Rybak MJ. Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin/dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 1998;42:2710-7.
35. Matsumura A, Simor AE. Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline and rifampin: a synergistic drug combination. Clin Infect Dis 1998;27:1554-5.
36. Messick CR, Pendland SL. In vitro activity of chloramphenicol alone and in combination with vancomycin, ampicillin or RP 59500 (quinupristin/dalfopristin) against vancomycin-resistant enterococci. Diagn Microbiol Infect Dis 1997;29:203-5.
37. Hill RLR, Smith CT, Seyed-Akhavani M, Casewell MW. Bactericidal and inhibitory activity of quinupristin/dalfopristin against vancomycin and gentamicin-resistant Enterococcus faecium. J Antimicrob Chemother 1997;39:23-8.
38. Hachem R, Raad R, Husni R, Whimbey E, Jacobson K, Rolston K. Quinupristin/dalfopristin (QD) plus minocycline (M) in the treatment of vancomycin-resistant Enterococcus faecium (VREF) infection in cancer patients (abstract 236). Clin Infect Dis 1998;27:965.
39. Lowy FD. Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest 2003;111:1265-73.
40. Livermore DM. Antibiotic resistance in staphylococci. Int J Antimicrob Agents 2000;16(suppl 1):S3-10.
41. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998;339:520-32.
42. Henwood CJ, Livermore DM, Johnson AP, James D, Warner M, Gardiner A. Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group. J Antimicrob Chemother 2000;46:931-40.
43. Paradisi F, Corti G, Messeri D. Antistaphylococcal (MSSA, MRSA, MSSE, MRSE) antibiotics. Med Clin North Am 2001;85:1-17.
44. Welch KE, Goff DA, Fish DN, Sierawski SJ, Paladino JA. A multicenter economic analysis of bacteremia caused by methicillin-resistant Staphylococcus aureus (abstract 1865). Presented at: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 26-29, 1999.
45. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003;36:53-9.
46. Cocito C, Di Giambattista M, Nyssen E, Vannuffel P. Inhibition of protein synthesis by streptogramins and related antibiotics. J Antimicrob Chemother 1997;39(suppl A):7-13.
47. Johnson AP, Livermore DM. Quinupristin/dalfopristin, a new addition to the antimicrobial arsenal. Lancet 1999;354:2012-3.
48. Almer LS, Shortridge VD, Nilius AM, Beyer JM, Soni NB, Bui MH, et al. Antimicrobial susceptibility and molecular characterization of community-acquired methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis 2002;43:225-32.
49. Lorian V, Fernandes F. Electron microscopy studies of the bactericidal effects of quinupristin/dalfopristin on Staphylococcus aureus. J Antimicrob Chemother 1999;43:845.
50. Lorian V, Amaral L, Fernandes F. RP 59500 postantibiotic effect defined by bacterial ultrastructure. Drugs Exp Clin Res 1995;21:125-8.
51. Lorian V, Esanu Y, Amaral L. Ultrastructure alterations of Staphylococcus aureus exposed to RP59500. J Antimicrob Chemother 1994;33:625-8.
52. Sieradzki K, Tomasz A. Suppression of beta-lactam antibiotic resistance in a methicillin-resistant Staphylococcus aureus through synergistic action of early cell wall inhibitors and some other antibiotics. J Antimicrob Chemother 1997;39(suppl A):47-51.
53. Vouillamoz J, Entenza JM, Reger C, Glauser MP, Moreillon P. Quinupristin-dalfopristin combined with beta-lactams for treatment of experimental endocarditis due to Staphylococcus aureus constitutively resistant to macrolide-lincosamide-streptogramin B antibiotics. Antimicrob Agents Chemother 2000;44:1789-95.
54. Lin L, Klutman NE, Lacy MK, Howard M, Hintorn DR, Horvat RT. Synergistic potential of quinupristin-dalfopristin and cefazolin against methicillin-resistant staphylococci from osteomyelitis patients (abstract A-142). Presented at: American Society of Microbiology 101st General Meeting, Orlando, May 20-24, 2001.
55. Fuchs PC, Barry AL, Brown SD. Interactions of quinupristin-dalfopristin with eight other antibiotics as measured by time-kill studies with 10 strains of Staphylococcus aureus for which quinupristin-dalfopristin alone was not bactericidal. Antimicrob Agents Chemother 2001;45:2662-5.
56. Vouillamoz J, Entenza JM, Giddey M, Glauser MP, Moreillon P. In vitro efficacy of Synercid (quinupristin/dalfopristin) (SYN) combined with other classes of antibiotics against methicillin-susceptible and resistant Staphylococcus aureus (MSSA and MRSA) (abstract E7). Presented at: 36th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 15-18, 1996.
57. Gfif K, Dierich MP, Pfaller K, Miglioli PA, Allerberger F. In vitro activity of fosfomycin in combination with various antistaphylococcal substances. J Antimicrob Chemother 2001;48:209-17.
58. Gugliotta JJ, Critchley IA, Draghi DC, Karginove E, Karlowsky JA, Sahm DF. Synergistic-killing of oxacillin-resistant S. aureus by quinupristin-dalfopristin and vancomycin (abstract E-328). Presented at: 41st Interscience Conference of Antimicrobial Agents and Chemotherapy, Chicago, September 22-25, 2001.
59. Hershberger E, Aeschilmann JR, Moldovan T, Rybak MJ. Evaluation of bactericidal activities of LY333328. vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin and RP59500 alone and in combination with rifampin, or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by time kill cure method. Antimicrob Agents Chemother 1999;43:717-23.
60. Scotten PG, Rigoli R, Vagia A. Combination of quinupristin/dalfopristin and glycopeptide in severe methicillin resistant staphylococcal infections failing previous glycopeptide regimens. Infection 2002;30:161-3.
61. Sgarabotto D, Cusinato R, Narne E, Scano F, Zignol M, Gambino A, et al. Synercid plus vancomycin for the treatment of severe methicillin resistant Staphylococcus aureus and coagulase-negative staphylococci infections: evaluation of 5 cases. Scand J Infect Dis 2002;34:122-6.
62. Moyenuddin M, Ohl CA, Williamson JC, Peacock JE. Disseminated oxacillin-resistant Staphylococcus aureus infection responsive to vancomyin and quinupristin-dalfopristin combination therapy. J Antimicrob Chemother 2003;51:202-3.
63. Moise-Broder PA, Forrest A, Jagodzinski LM, Paladino JA, Schentag JJ. Methicillin-resistant Staphylococcus aureus (MRSA) infections in hospitalized patients failing vancomycin (Vm): cost-effectiveness of increasing Vm versus adding quinupristin-dalfopristin (Q/D) to Vm (abstract 578). Presented at: 40th Annual Meeting of the Infectious Disease Society of America, Chicago, October 24-27, 2002.
64. Sambatakou H, Giamarellos-Bourboulis EJ, Grecka P, Chryssouli Z, Giamarellou H. In-vitro activity and killing effect of quinupristin/ dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against methicillin-resistant isolates. J Antimicrob Chemother 1998;41:349-55.
65. Saleh-Mghir A. Ameur N, Massias L, Feger C, Carbon C, Cremieux AC. Combination of Synercid (Syn) and rifampin (Rif) is highly synergistic in experimental Staphylococcus aureus joint prosthesis infections (abstract 994). Presented at: 40th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 17-20, 2000.